{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:29:10Z","timestamp":1770071350372,"version":"3.49.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>After taking all of the CME courses in this supplement the reader will be able to:<\/jats:p>\n                  <jats:p>Describe the basic biology of various leukemias, multiple myeloma, and myelodysplastic syndrome (MDS). Discuss new targeted treatment strategies for hematologic malignancies. Understand the rationale for the use of nontraditional cytotoxic agents such as arsenic trioxide in the treatment of hematologic malignancies. Examine the role of arsenic trioxide and other novel agents in early-versus accelerated-stage hematologic disease. Discuss the preclinical and clinical efficacy of arsenic trioxide and various agents in treating acute promyelocytic leukemia, MDS, and multiple myeloma.<\/jats:p>\n                  <jats:p>Access CME test online and receive one hour category 1 credit at CME.TheOncologist.com<\/jats:p>\n                  <jats:p>Bcr-Abl-positive leukemias include chronic myelogenous leukemia (CML), both myeloid and lymphoid blast-phase CML, and some cases of acute lymphoblastic leukemia. The chimeric bcr-abl gene codes for a tyrosine kinase that is constitutively activated in the leukemic cells and plays the central role in leukemogenesis. Hematologic malignancies, including Bcr-Abl-positive leukemias, also frequently have overactivity of the Ras signaling pathway, leading to abnormal transduction of growth and survival signals. New and investigational therapeutic options that target these specific molecular defects of leukemic cells include the tyrosine kinase inhibitor imatinib mesylate (STI571) and farnesyltransferase inhibitors (R115777, SCH66336), which block localization of Ras proteins to the cell membrane. While single-agent therapy with these new agents may produce hematologic and cytogenetic remissions in patients with Bcr-Abl-positive leukemias, molecular remissions are less common, and resistance may develop. Therefore, the development of a multifaceted therapeutic approach to these leukemias is of great interest. Arsenic trioxide (ATO), which has significant activity in patients with relapsed and refractory acute promyelocytic leukemia, is a potential addition to the therapeutic arsenal. While some of the molecular activities of ATO are specific to acute promyelocytic leukemia, arsenicals also have a broad variety of antineoplastic properties that may be useful in combination therapy with agents that target specific molecular defects of Bcr-Abl-positive leukemias.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.7-suppl_1-30","type":"journal-article","created":{"date-parts":[[2004,8,25]],"date-time":"2004-08-25T16:25:30Z","timestamp":1093451130000},"page":"30-38","source":"Crossref","is-referenced-by-count":24,"title":["Multifaceted Approach to the Treatment of Bcr-Abl-Positive Leukemias"],"prefix":"10.1093","volume":"7","author":[{"given":"Michael","family":"O'Dwyer","sequence":"first","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2002,4,1]]},"reference":[{"key":"2021122216415298900_R1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2796.2001.00823.x","article-title":"Chronic myelogenous leukaemia\u2014new therapeutic principles","volume":"250","author":"O'Dwyer","year":"2001","journal-title":"J Intern Med"},{"key":"2021122216415298900_R3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia [editorial]","volume":"344","author":"Goldman","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.286.8.895","article-title":"Chronic myelogenous leukemia","volume":"286","author":"Kalidas","year":"2001","journal-title":"JAMA"},{"key":"2021122216415298900_R8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8588(05)70495-0","article-title":"Biology of chronic myelogenous leukemia","volume":"12","author":"Verfaillie","year":"1998","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122216415298900_R9","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","article-title":"In vitro transformation of immature hematopoietic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome","volume":"84","author":"McLaughlin","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122216415298900_R10","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122216415298900_R11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0022-2143(97)90192-X","article-title":"Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR\/ABL positive clone?","volume":"129","author":"Verfaillie","year":"1997","journal-title":"J Lab Clin Med"},{"key":"2021122216415298900_R12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest"},{"key":"2021122216415298900_R13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"2021122216415298900_R14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R16","first-page":"435a","article-title":"Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy","volume":"98","author":"Kreil","year":"2001","journal-title":"Blood"},{"key":"2021122216415298900_R17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"Coutre","year":"2000","journal-title":"Blood"},{"key":"2021122216415298900_R18","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"2021122216415298900_R19","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2021122216415298900_R20","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.V98.7.2039","article-title":"Chronic myeloid leukemia: current treatment options","volume":"98","author":"Goldman","year":"2001","journal-title":"Blood"},{"key":"2021122216415298900_R21","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"key":"2021122216415298900_R22","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials","volume":"89","author":"Chronic Myeloid Leukemia Trialists' Collaborative Group","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2021122216415298900_R23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"2021122216415298900_R24","first-page":"846a","article-title":"Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML","volume":"98","author":"O'Dwyer","year":"2001","journal-title":"Blood"},{"key":"2021122216415298900_R25","first-page":"846a","article-title":"PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia. UK PISCES Group","volume":"98","author":"OBrien","year":"2001","journal-title":"Blood"},{"issue":"3 suppl 7","key":"2021122216415298900_R26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0037-1963(01)90126-X","article-title":"Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies","volume":"38","author":"Karp","year":"2001","journal-title":"Semin Hematol"},{"key":"2021122216415298900_R27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1999.17.3.1071","article-title":"RAS and leukemia: from basic mechanisms to gene-directed therapy","volume":"17","author":"Beaupre","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122216415298900_R28","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"key":"2021122216415298900_R29","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood.V97.5.1404","article-title":"Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia","volume":"97","author":"Peters","year":"2001","journal-title":"Blood"},{"key":"2021122216415298900_R30","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood.V97.5.1399","article-title":"Treatment of Bcr\/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336","volume":"97","author":"Reichert","year":"2001","journal-title":"Blood"},{"issue":"part 1","key":"2021122216415298900_R31","first-page":"617a","article-title":"Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336","volume":"98","author":"Hoover","year":"2001","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122216415298900_R32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.6-suppl_2-3","article-title":"History of the development of arsenic derivatives in cancer therapy","volume":"6","author":"Waxman","year":"2001","journal-title":"The Oncologist"},{"key":"2021122216415298900_R33","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1182\/blood.V89.9.3487","article-title":"Delicious poison: arsenic trioxide for the treatment of leukemia [letter]","volume":"89","author":"Kwong","year":"1997","journal-title":"Blood"},{"key":"2021122216415298900_R34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/jama.1931.02730010007002","article-title":"Arsenic as a therapeutic agent in chronic myelogenous leukemia","volume":"97","author":"Forkner","year":"1931","journal-title":"JAMA"},{"key":"2021122216415298900_R35","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood"},{"key":"2021122216415298900_R36","first-page":"170","article-title":"Thirty-two cases of treating acute promyelocytic leukemia by Ailing-1 (cancer-cure-1) therapy combined with syndrome differentiation treatment of traditional Chinese medicine","volume":"12","author":"Sun","year":"1992","journal-title":"Chin J Combinat Tradit Chin Med West Med"},{"key":"2021122216415298900_R37","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1182\/blood.V87.8.3404.bloodjournal8783404","article-title":"Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice","volume":"87","author":"Zhang","year":"1996","journal-title":"Blood"},{"key":"2021122216415298900_R38","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","article-title":"Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide","volume":"339","author":"Soignet","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122216415298900_R39","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122216415298900_R40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/jnci\/90.2.124","article-title":"Arsenic trioxide as an inducer of apoptosis and loss of PML\/RAR\u03b1 protein in acute promyelocytic leukemia cells","volume":"90","author":"Shao","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2021122216415298900_R41","first-page":"3345","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells","volume":"89","author":"Chen","year":"1997","journal-title":"Blood"},{"key":"2021122216415298900_R42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9","article-title":"Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis","volume":"177","author":"Chen","year":"1998","journal-title":"J Cell Physiol"},{"key":"2021122216415298900_R43","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/sj.leu.2401900","article-title":"Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis","volume":"14","author":"Kitamura","year":"2000","journal-title":"Leukemia"},{"key":"2021122216415298900_R44","first-page":"3053","article-title":"Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"2021122216415298900_R45","first-page":"786a","article-title":"Glutathione depletion restores arsenic-sensitivity to As2O3-resistant APL cells","volume":"42","author":"Davison","year":"2001","journal-title":"Proc Am Assoc Cancer Res"},{"key":"2021122216415298900_R46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V93.1.268","article-title":"Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system","volume":"93","author":"Dai","year":"1999","journal-title":"Blood"},{"key":"2021122216415298900_R47","doi-asserted-by":"crossref","first-page":"36062","DOI":"10.1074\/jbc.M007204200","article-title":"Inhibition of NF-\u03baB activation by arsenite through reaction with a critical cysteine in the activation loop of I\u03baB kinase","volume":"275","author":"Kapahi","year":"2000","journal-title":"J Biol Chem"},{"key":"2021122216415298900_R48","first-page":"3409","article-title":"BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity","volume":"60","author":"Puccetti","year":"2000","journal-title":"Cancer Res"},{"key":"2021122216415298900_R49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V95.3.1014.003k04_1014_1022","article-title":"Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL.","volume":"95","author":"Perkins","year":"2000","journal-title":"Blood"},{"key":"2021122216415298900_R50","first-page":"37","article-title":"Mechanism by which arsenic trioxide downregulates Bcr-Abl levels and potentiates Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells","volume":"7","author":"Nimmanapalli","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122216415298900_R51","first-page":"14a","article-title":"Use of arsenic trioxide in the treatment of chronic myelogenous leukemia: clinical efficacy in 34 patients","volume-title":"Program and Abstracts: Advances in Cancer Differentiation Therapy\u2014A Meeting Combining the East and the West","author":"Hu","year":"2000"},{"key":"2021122216415298900_R52","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.leu.2402104","article-title":"Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Bcr-Abl-positive acute leukemia cells","volume":"15","author":"Porosnicu","year":"2001","journal-title":"Leukemia"},{"key":"2021122216415298900_R53","first-page":"839a","article-title":"Preclinical evaluation of the efficacy of STI571 in combination with a variety of novel anticancer agents","volume":"98","author":"Ros\u00e9e","year":"2001","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.7-suppl_1-30","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.7-suppl_1-30","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/S1\/30\/41838939\/oncolo_7_s1_30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/7\/S1\/30\/41838939\/oncolo_7_s1_30.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T19:42:28Z","timestamp":1640202148000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/7\/S1\/30\/6387737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":53,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2002,4,1]]},"published-print":{"date-parts":[[2002,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.7-suppl_1-30","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,4,1]]},"published":{"date-parts":[[2002,4,1]]}}}